Plasma levels of adipokines and insulin are associated with markers of brain atrophy and cognitive decline in the spectrum of Alzheimer's Disease.
Détails
ID Serval
serval:BIB_8D266B639AD0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Plasma levels of adipokines and insulin are associated with markers of brain atrophy and cognitive decline in the spectrum of Alzheimer's Disease.
Périodique
Progress in neuro-psychopharmacology & biological psychiatry
Collaborateur⸱rice⸱s
Alzheimer's Disease Neuroimaging Initiative
ISSN
1878-4216 (Electronic)
ISSN-L
0278-5846
Statut éditorial
Publié
Date de publication
30/08/2024
Peer-reviewed
Oui
Volume
134
Pages
111077
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
The discovery that metabolic alterations often coexist with neurodegenerative conditions has sparked interest in the examination of metabolic regulatory factors as potential modulators of brain health. Here, we examined the role of adipokines (leptin, adiponectin, resistin, and IL6) and insulin on different markers of brain atrophy in participants on the spectrum of Alzheimer's Disease. We included 566 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset with 1063 follow-up time points (average follow-up: one year); and examined the association between metabolic regulatory factors and volumetric MRI values, white matter hyperintensities, and measures of cognitive impairment. Higher leptin, resistin, IL6, and insulin were associated with markers of cerebral atrophy, such as lower total brain volume, or higher ventricular volume. Higher leptin and resistin were also associated with greater impairment in daily life activities. Higher adiponectin was associated with lower ventricle volume. There was no association between adipokines or insulin with white matter hyperintensities. Our findings indicate a co-occurrence between alterations in metabolic regulatory factors and in brain volume along the preclinical to clinical spectrum of Alzheimer's Disease. These results suggest that strategies aimed at promoting metabolic health may positively impact brain health.
Mots-clé
Humans, Alzheimer Disease/blood, Alzheimer Disease/pathology, Alzheimer Disease/diagnostic imaging, Atrophy/pathology, Male, Female, Aged, Adipokines/blood, Cognitive Dysfunction/blood, Cognitive Dysfunction/diagnostic imaging, Cognitive Dysfunction/pathology, Brain/diagnostic imaging, Brain/pathology, Magnetic Resonance Imaging, Insulin/blood, Biomarkers/blood, Aged, 80 and over, Adipokines, Alzheimer's, Brain atrophy, Inflammation, Insulin resistance, Magnetic resonance imaging
Pubmed
Web of science
Création de la notice
11/07/2024 15:43
Dernière modification de la notice
30/07/2024 7:02